中访网数据 广东众生药业股份有限公司于2026年1月16日召开第九届董事会第二次会议，审议通过了其 控股子公司广东众生睿创生物科技有限公司与齐鲁制药有限公司就RAY1225注射液项目签署许可协议 的核心议案。根据协议，众生睿创将授予齐鲁制药在中国地区（包括中国大陆、香港、澳门、台湾）内 对RAY1225注射液进行生产与商业化销售的独家权利，而众生睿创保留该许可知识产权的全部权益， 并在产品获批后作为药品上市许可持有人。此次合作旨在加速公司创新药的上市商业化进程，并聚焦于 核心研发业务。协议约定，在满足相关条款的前提下，众生睿创将获得首付款及里程碑付款总额高达人 民币10亿元，其中包括人民币2亿元的首付款以及最高可达人民币8亿元的开发和销售里程碑付款。产品 上市后，众生睿创还将有权从许可产品的净销售额中获得双位数的销售提成。此次授权不影响众生睿创 对RAY1225注射液在海外市场的全部权益。该决议已获董事会全票通过，标志着众生药业在创新药价 值实现路径上迈出关键一步。 ...

Core Viewpoint - Gland Pharma has undergone significant personnel changes to enhance its global business development and strategic cooperation, reflecting a shift towards innovation and internationalization in its operations [4][5]. Group 1: Personnel Changes - On January 3, Gland Pharma dismissed its Vice President and CFO, Sun Cheng, appointing internal veteran Zhou Li as the acting CFO [1][3]. - On January 13, Dr. John Wang was appointed as Senior Vice President and Chief Strategy Officer, responsible for business development and strategic partnerships [3][4]. - Dr. Wang brings over 30 years of experience in the pharmaceutical industry, having held key positions in major companies such as Sanofi, Merck, and Eli Lilly [3][4]. Group 2: Strategic Shift - Gland Pharma's leadership transition is part of a broader strategy to shift focus from being a domestic insulin leader to innovating and commercializing new drugs globally [5]. - The company aims to enhance its capabilities in global financing, mergers, and acquisitions, necessitating the recruitment of talent with international expertise [5]. - The appointment of Dr. Wang is seen as a move to strengthen global business expansion and transition from "product export" to "global operations" [5]. Group 3: Financial Performance - Gland Pharma reported a 35.73% year-on-year revenue growth and over 122% increase in net profit, despite the personnel changes occurring during a period of strong performance [4][6]. - However, the company faced challenges in the third quarter of 2025, with total revenue declining by 9.4% to 980 million yuan and net profit dropping by 26% [6]. - The accounts receivable surged to 530 million yuan, a 147.86% increase compared to the previous year, indicating potential risks related to credit policies and cash flow [6].

Core Viewpoint - The Hong Kong stock market has experienced a significant rise in innovative pharmaceuticals, with the Hang Seng Healthcare Index increasing by 102.76% from the beginning of the year to its peak in September, followed by a decline of 19.06% by December 22. Despite this, the company He Yu has seen a remarkable stock price increase of 370.95% this year, driven by the approval of its core product, Pimicotinib, in China [1][2][5]. Group 1: Product Approval and Market Impact - He Yu announced the approval of its drug Beijiemai (Pimicotinib) by the NMPA, marking it as the first systemic treatment for tenosynovial giant cell tumor (TGCT) in China [2][5]. - The approval process for Beijiemai was expedited, receiving priority review in May and being approved within six months after its NDA application was accepted [6][7]. - The drug has shown strong and durable tumor relief efficacy in clinical trials, providing significant evidence for its long-term safety and effectiveness [6][7]. Group 2: Financial and Market Potential - Pimicotinib is expected to generate substantial revenue, with estimates suggesting it could reach peak sales of approximately $1.5 billion globally [8][9]. - The company has secured a lucrative partnership with Merck, which includes an upfront payment of $70 million and potential total transaction value of up to $606 million, reflecting strong confidence in the drug's market potential [7][9]. - The approval of Pimicotinib is anticipated to enhance the company's cash flow, supporting further innovation and development of its oncology pipeline [9][10]. Group 3: Innovation Pipeline and Valuation - He Yu has established a robust pipeline of 22 differentiated innovative drugs, focusing on precision oncology and immunotherapy, with several candidates showing potential for being first-in-class or best-in-class [9][10]. - The company has been actively repurchasing shares, with a total of 39 buybacks this year, indicating a commitment to returning value to shareholders [10]. - Compared to other biopharma companies, He Yu's price-to-sales (P/S) ratio of 13.38 suggests significant upside potential in valuation, especially with the successful commercialization of Pimicotinib [10].

Core Insights - Multiple domestic innovative antiviral drugs for influenza have been approved this year, leading to significant market attention, with 2025 being referred to as the "Year of Domestic Influenza Innovative Drugs" [1][10] - The rapid progress in domestic influenza innovative drugs reflects the continuous improvement of China's pharmaceutical innovation capabilities [1][10] Group 1: Market Dynamics - From March to July 2025, three antiviral drugs (Mashurashave tablets, Angladive tablets, and Maseiluo tablets) were approved, with two more (Madiroshave and Mapashirashave) completing clinical trials and applying for market entry [2][11] - The sales of these domestic innovative drugs are steadily increasing, indicating recognition of their efficacy and safety [2][11] - The global influenza antiviral market is projected to grow significantly, with China's market expected to reach 26.9 billion yuan by 2028, growing at a compound annual growth rate (CAGR) of 20.2% from 2024 to 2028 [3][12] Group 2: Competitive Landscape - The domestic new drugs are not mere copies of imported drugs but have undergone targeted optimizations, such as reducing drug resistance risks and improving safety for pediatric use [2][11] - Despite strong demand, the Chinese influenza drug market has been dominated by imported drugs, with Oseltamivir holding over 80% market share in 2023 [3][12] - The acceleration of domestic new drug approvals is expected to lead to rapid sales growth, enhancing company performance [3][12] Group 3: Policy and Industry Support - Recent regulatory reforms by the National Medical Products Administration have improved drug approval efficiency, with 48 innovative drugs approved in 2024, ranking second globally [7][16] - The Chinese biopharmaceutical industry is rapidly developing, with the total value of innovative drug business development (BD) transactions exceeding 100 billion USD in 2025, projected to reach 265.9 billion USD by 2030 [7][16] Group 4: Future Outlook - The overall industry sentiment is expected to improve as positive catalysts continue to emerge, with recent developments in innovative drug insurance negotiations and international conferences [8][17] - Investors are encouraged to consider ETFs that cover high-quality innovative pharmaceutical companies in both Hong Kong and A-shares to mitigate individual stock risks and capitalize on the opportunities in China's innovative drug sector [8][17]

天风证券认为，以BD为突破口（包括传统BD、NewCo、Co-Co），中国创新药将系统参与到全球创新 药市场中，而当前全球药品市场规模是中国药品市场规模的6倍左右，这将显著打开中国创新药的商业 化价值，整体生态体系也将愈发健康成熟，中国正加速迈入产品研发与商业销售的双轮驱动阶段。12月 7日，国家医保局、人力资源社会保障部发布《国家基本医疗保险、工伤保险和生育保险药品目录 （2025 年）》以及首版《商业健康保险创新药品目录（2025 年）》，要求进一步推动商业健康保险与 基本医保的有效衔接。东方证券指出，首版商保目录落地，开启中国创新药"新黄金十年"。总体来看， 首版商保目录具有3个看点：1）激烈角逐谨慎落地，121个通过形式审查的新药最终只有19个进入目 录，远低于惠民保特药平均41款的体量；2）5款国产CAR-T全部入场，2款AD新药同时入选，显示出商 保谈判对高临床疗效和高价值创新的认可信号；3）肿瘤仍是主战场，19款中有14款入选，占比达 74%。本次商保目录价格谈判只是一个开始，后续商保目录制定和价格谈判规则会在探索中趋于成熟， 商保作为医保补充背后是国家治理的决心，相关配套政策有望逐步落地。上述 ...

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical industry Core Insights - The pharmaceutical industry is gradually stabilizing, with a total revenue of 16,766.9 billion yuan in the first three quarters of 2025, reflecting a slight decline of 0.7% year-on-year. The net profit attributable to shareholders decreased by 1.1% to 1,427.5 billion yuan, while the net profit excluding non-recurring items fell by 8.5% to 1,219.9 billion yuan [3][13][37] - Among the 388 selected pharmaceutical companies, 197 companies achieved revenue growth, accounting for 51%, while 189 companies reported positive net profit growth, representing 49% [3][13] - The third quarter of 2025 saw a positive revenue growth rate of 1.9% year-on-year, with net profit showing stable growth [14] Summary by Sections Overall Industry Performance - The pharmaceutical industry experienced a revenue decline of 0.7% in the first three quarters of 2025, with a total revenue of 16,766.9 billion yuan. The net profit attributable to shareholders decreased by 1.1% to 1,427.5 billion yuan [3][37] - The first three quarters showed a quarterly revenue of 5,586 billion yuan in Q1, 5,593 billion yuan in Q2, and 5,588 billion yuan in Q3, with Q3 marking a return to positive growth [14][16] Sector Performance - **Innovative Drugs and Formulations**: Revenue of 3,437.8 billion yuan (+0.6%) and net profit of 342.8 billion yuan (+5.0%) [4] - **Medical Devices**: Revenue of 1,457 billion yuan (-2.4%) and net profit of 265 billion yuan (-14.4%) [5] - **CXO**: Revenue of 695.7 billion yuan (+13.0%) and net profit of 165.4 billion yuan (+60.0%) [5][30] - **Active Pharmaceutical Ingredients**: Revenue of 782.1 billion yuan (-1.5%) and net profit of 114.2 billion yuan (+6.6%) [5] - **Life Sciences Upstream**: Revenue of 60.2 billion yuan (+0.1%) and net profit of 4.4 billion yuan (+15.6%) [5] - **Medical Services**: Revenue of 436 billion yuan (+0.4%) and net profit of 57.3 billion yuan (-13.8%) [5] - **Blood Products**: Revenue of approximately 176 billion yuan (+0.5%) and net profit of approximately 37.7 billion yuan (-20.0%) [5] - **Retail Pharmacies**: Revenue of 859 billion yuan (+0.7%) and net profit of 35.2 billion yuan (+8.9%) [6] - **Pharmaceutical Distribution**: Revenue of 6,087.3 billion yuan (+1.4%) and net profit of 116.8 billion yuan (+5.5%) [6] - **Traditional Chinese Medicine**: Revenue of 2,506 billion yuan (-3.6%) and net profit of 292.7 billion yuan (-0.5%) [6] - **Vaccine Sector**: Revenue of 174 billion yuan (-49.2%) and net profit of -9 billion yuan (-121.6%) [6] Profitability Analysis - The overall industry saw a decline in gross profit margin and net profit margin, with the gross profit margin at 33.7% and net profit margin at 8.5% [37][40] - The CXO sector exhibited the highest growth in net profit, increasing by 60% [31][35] - The medical device sector faced significant profit pressure, with a net profit decline of 14.4% [5][30]

Core Viewpoint - The Chinese innovative drug market is experiencing a "structural turning point," which is expected to reverse the downward trend in the pharmaceutical industry [3][11]. Industry Overview - The domestic pharmaceutical terminal sales have shown negative growth since 2024, with over 30% of regulated pharmaceutical companies reporting losses in the first half of this year [3][7]. - The low concentration in several sub-sectors, particularly in the generic drug industry, has led to "price internalization," which is a key constraint on the development of the Chinese pharmaceutical industry [3][7]. Innovative Drug Market Potential - Despite the challenges, there has been a significant emergence of innovative drug achievements in China this year, with innovative drugs rapidly increasing their market share and frequent external licensing deals [3][5]. - The market share of innovative drugs in China is currently only 8.6%, compared to over 70% in the US and European countries, indicating substantial growth potential [5][17]. Financial Performance - The overall revenue of pharmaceutical companies in China decreased by 5.5% year-on-year, but innovative transformation companies and some emerging innovative drug firms have maintained good growth and profitability [3][7]. - In the first half of 2025, 34.3% of the surveyed companies reported losses, highlighting the financial strain within the industry [7][10]. Market Dynamics - The average price level of generic drugs has been further reduced due to policies on price governance and drug price control, leading to intensified competition and downward pressure on prices [8][9]. - The Chinese pharmaceutical industry is still primarily driven by domestic circulation, with exports contributing only 10% to 15% of industrial revenue over the past four years [7][10]. Future Outlook - The commercialization of innovative drugs is expected to become the core driving force for industry growth during the downturn [11][12]. - The market for innovative drugs (including biosimilars) reached 120 billion yuan in 2023, with a growth rate of 27%, indicating a robust pipeline of new products [12][17]. Export Performance - From January to October 2025, China's pharmaceutical product exports reached 91.17 billion USD, a year-on-year increase of 3.5%, with a significant growth in formulation exports [15][16]. - The proportion of formulation exports in total pharmaceutical exports reached a historical high of 16.1%, indicating a shift in the export landscape [16]. Challenges and Opportunities - The domestic innovative drug market is still not large enough, and the pricing support system needs improvement to sustain growth [17][21]. - The industry faces challenges from funding shortages and low accessibility of innovative drugs, with about 88% of respondents in a survey indicating insufficient funding for innovative drug development [17][21]. Strategic Recommendations - To enhance the commercialization efficiency of innovative drugs, the industry should focus on reducing competition among numerous players and fostering a healthier market structure [23][24]. - Building an international innovation platform is crucial for Chinese pharmaceutical companies to capture a larger share of the global innovation dividend [24].

Group 1: Market Overview - In the US and five European countries, innovative drugs account for 70%-80% of the local market, while in China, the market share of innovative drugs is only 8.6% [1][10] - The Chinese innovative drug market is experiencing a "structural turning point," which is expected to reverse the downward trend in the pharmaceutical industry [1] - The domestic pharmaceutical terminal sales are projected to show negative growth starting in 2024, with over 30% of regulated pharmaceutical companies reporting losses in the first half of this year [1][3] Group 2: Industry Challenges - The pharmaceutical industry is facing a survival crisis due to external growth factors diminishing, and the capital market's enthusiasm for business development (BD) transactions cooling down [3] - The low concentration in several sub-sectors, particularly in the generic drug industry, has led to price competition, which is a key constraint on the development of the Chinese pharmaceutical industry [3][4] - The average price level of generic drugs has been further reduced due to policies on price governance and drug price comparison [4] Group 3: Innovative Drug Growth - Despite the overall revenue decline in the pharmaceutical industry, innovative drug companies have maintained good growth and profitability, with some achieving record high revenues [1][7] - The market size of innovative drugs (including biosimilars) reached 120 billion yuan in 2023, with a growth rate of 27% [7] - The revenue growth rate for biological products was 2.2%, with profit growth at 10.6%, indicating a strong performance in the innovative drug sector [8][7] Group 4: Regulatory and Policy Developments - The National Healthcare Security Administration has announced reforms to improve the immediate settlement of medical insurance funds, which is expected to alleviate the financial pressure on hospitals and improve drug payment timelines [5][6] - The implementation of policies to expand the scope of drug procurement and price control is expected to further impact the market dynamics [4][10] Group 5: Future Opportunities - The commercial potential of innovative drugs is anticipated to become the core driver of industry growth during the downturn [7] - The increasing number of innovative drug approvals and the shift in hospital medication structure are expected to enhance the market share of innovative products [7] - The industry is encouraged to build international innovation platforms to capture a larger share of the global market [2][18]

Group 1: Industry Insights - Multiple innovative pharmaceutical companies have received significant attention from both domestic and foreign institutional investors, with BeiGene receiving inquiries from 88 institutions and Zai Lab from 36 institutions [1] - The Chinese pharmaceutical industry is entering a critical phase characterized by "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - By 2026, opportunities in innovative commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions are expected to emerge [1] Group 2: Market Performance - As of November 24, 2025, the CSI Hong Kong Innovative Drug Index rose by 3.05%, with the Hong Kong Innovative Drug ETF (513120) increasing by 2.23% and achieving a trading volume exceeding 4.7 billion [2] - Over the past six months, the Hong Kong Innovative Drug ETF has accumulated a return of 33.71% [2] - The latest scale of the Hong Kong Innovative Drug ETF reached 24.102 billion, with continuous net inflows over the past six days totaling 170 million [2] Group 3: Company Developments - Traditional pharmaceutical companies like Heng Rui Medicine and Hansoh Pharmaceutical have successfully completed their innovation transformations, while companies like Bai Li Tianheng have emerged with globally innovative products [1] - Chinese pharmaceutical companies are becoming significant sources of innovation for multinational pharmaceutical firms, with improvements in their global competitiveness [1]

Group 1 - The Hong Kong pharmaceutical sector showed strength on November 24, with companies like 3SBio rising over 7% and Hengrui Medicine and Innovent Biologics increasing by more than 4% [1] - The Hong Kong Innovative Drug ETF (159567) rose approximately 2.2% by 9:51 AM, with a trading volume exceeding 300 million yuan [1] - As of last Friday, the product's shares increased by 1.105 billion shares this month, reaching a total of 9.922 billion shares, nearing the 10 billion mark [1] Group 2 - Institutions believe that the Chinese pharmaceutical industry has entered a critical phase of "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - Companies are actively exploring diversified overseas paths, with a focus on opportunities arising from innovation commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions by 2026 [1] - The Hong Kong Innovative Drug ETF (159567) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, reflecting the performance characteristics of listed companies in the innovative drug sector within the Stock Connect framework [1]